Abstract
The standard version of the wing somatic mutation and recombination test (SMART) in Drosophila melanogaster was employed in order to evaluate the genotoxic potential of metronidazole (MTZ) as a function of exposure concentration. MTZ was administered by chronic feeding of 3-day-old larvae with the parenteral solution at 0, 500, 1000 and 2000 μg/ml until pupation. The marker-heterozygous progeny (mwh+/+flr3) with phenotypically wild-type wings was analyzed. Non significant differences were found between control and each MTZ concentration tested for single small spots (SSS) frequencies. Large single spots (LSS) and twin spots (TS) were significantly increased with the higher dose. MTZ treatments with 1000 and 2000 μg/ml also significantly increased the frequency of Total spots. These findings suggest that MTZ is genotoxic in the present experimental conditions and induces recombinagenesis and/or gene conversion, two major mechanisms that cause loss of heterocigosity and could play an important role in tumorigenesis and carcinogenesis processes.
Keywords: Drosophila, genotoxicity, metronidazole (MTZ), loss of heterozygosity, wing spot assay.
Current Drug Safety
Title:Metronidazole Induced DNA Damage in Somatic Cells of Drosophila melanogaster
Volume: 8 Issue: 3
Author(s): Ana Maria Palermo and Marta Dolores Mudry
Affiliation:
Keywords: Drosophila, genotoxicity, metronidazole (MTZ), loss of heterozygosity, wing spot assay.
Abstract: The standard version of the wing somatic mutation and recombination test (SMART) in Drosophila melanogaster was employed in order to evaluate the genotoxic potential of metronidazole (MTZ) as a function of exposure concentration. MTZ was administered by chronic feeding of 3-day-old larvae with the parenteral solution at 0, 500, 1000 and 2000 μg/ml until pupation. The marker-heterozygous progeny (mwh+/+flr3) with phenotypically wild-type wings was analyzed. Non significant differences were found between control and each MTZ concentration tested for single small spots (SSS) frequencies. Large single spots (LSS) and twin spots (TS) were significantly increased with the higher dose. MTZ treatments with 1000 and 2000 μg/ml also significantly increased the frequency of Total spots. These findings suggest that MTZ is genotoxic in the present experimental conditions and induces recombinagenesis and/or gene conversion, two major mechanisms that cause loss of heterocigosity and could play an important role in tumorigenesis and carcinogenesis processes.
Export Options
About this article
Cite this article as:
Palermo Maria Ana and Mudry Dolores Marta, Metronidazole Induced DNA Damage in Somatic Cells of Drosophila melanogaster, Current Drug Safety 2013; 8 (3) . https://dx.doi.org/10.2174/15748863113089990035
DOI https://dx.doi.org/10.2174/15748863113089990035 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of Matrix Metalloproteinases in Animal Models of Ischemic Stroke
Current Vascular Pharmacology Targeted Cancer Therapeutics: Biosynthetic and Energetic Pathways Characterized by Metabolomics and the Interplay with Key Cancer Regulatory Factors
Current Pharmaceutical Design MicroRNAs in Skin Response to UV Radiation
Current Drug Targets The Potential of Modulating Small RNA Activity In Vivo
Mini-Reviews in Medicinal Chemistry Adenosine A1 Receptors in the Central Nervous System: Their Functions in Health and Disease, and Possible Elucidation by PET Imaging
Current Medicinal Chemistry Pyrimidine Salvage Pathway in Mycobacterium tuberculosis
Current Medicinal Chemistry Design of Phenotypic Screens for Bioactive Chemicals and Identification of their Targets by Genetic and Proteomic Approaches
Combinatorial Chemistry & High Throughput Screening Oxidative Stress Modulation Through Habitual Physical Activity
Current Pharmaceutical Design Cancer-Associated Carbonic Anhydrases and Their Inhibition
Current Pharmaceutical Design Targeted Therapies in Solid Tumours: Pinpointing the Tumours Achilles Heel
Current Pharmaceutical Design Lipogenic Enzymes as Therapeutic Targets for Obesity and Diabetes
Current Pharmaceutical Design Is the Clinical Use of Cannabis by Oncology Patients Advisable?
Current Medicinal Chemistry SiRNA Nanotherapeutics _The Panacea of Diseases?
Current Gene Therapy Botanical Therapeutics (Part II): Antimicrobial and In Vitro Anticancer Activity against MCF7 Human Breast Cancer Cells of Chamomile, Parsley and Celery Alcoholic Extracts
Anti-Cancer Agents in Medicinal Chemistry Biotransformation of Silybin and its Congeners
Current Drug Metabolism Recent Approaches in Chemoprevention of Prostate Cancer
Current Cancer Drug Targets Cytotoxic Nucleoside Analogues: Different Strategies to Improve their Clinical Efficacy
Current Medicinal Chemistry Synthetic Aspects and First-time Assessment of 2-amino-1,3-selenazoles Against Mycobacterium tuberculosis
Letters in Drug Design & Discovery Isolation and Characterisation of Acetylcholinesterase Inhibitors from Aquilaria subintegra for the Treatment of Alzheimer’s Disease (AD)
Current Alzheimer Research Parkinson’s Disease: Is there a Role for Dietary and Herbal Supplements?
CNS & Neurological Disorders - Drug Targets